PROSTATE CANCER METASTATIC
Clinical trials for PROSTATE CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new PROSTATE CANCER METASTATIC trials appear
Sign up with your email to follow new studies for PROSTATE CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets resistant prostate cancer
Disease control CompletedThis early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete,…
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE1 • Sponsor: Arvinas Androgen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New cocktail of drugs shows promise for tough prostate cancer
Disease control CompletedThis early-phase trial tested a combination of four drugs—apalutamide, abiraterone, docetaxel, and prednisone—in 16 men with metastatic castrate-resistant prostate cancer, a form of the disease that no longer responds to standard hormone therapy. The main goal was to find a safe …
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control CompletedThis study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New imaging comparison could improve prostate cancer monitoring
Knowledge-focused CompletedThis completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor …
Matched conditions: PROSTATE CANCER METASTATIC
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Which prostate cancer drug is kinder to your brain? new study aims to find out
Knowledge-focused CompletedThis study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI learns from 14,000 prostate scans to spot aggressive cancers
Knowledge-focused CompletedThis study created a massive, secure database of over 14,000 prostate MRI scans from men with or suspected of having prostate cancer. Researchers used this data to train artificial intelligence (AI) models to better tell apart slow-growing from aggressive cancers, predict if canc…
Matched conditions: PROSTATE CANCER METASTATIC
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC